NeuroAiD™ is a medicine indicated for post-stroke rehabilitation.

NeuroAiD™ was registered by the Sino FDA in 2001 after being evaluated in two randomized, double-blind, positive control prospective phase III clinical trials. Since then, NeuroAiD™ has been widely available in China and is now a hospital prescription reimbursed through health coverage.

Recognizing the potential of NeuroAiD™ in addressing a major therapeutic gap, Moleac, a biopharmaceutical company headquartered in Singapore and with an office in France, has acquired the exclusive right to develop and market this product internationally. NeuroAiD™ is a registered trademark of Moleac Pte Ltd.

Following national regulations in each market, NeuroAiD™ has filed for registration under various schemes, which includes dietary supplement, complementary medicine, and drug To date, NeuroAiD™ is available in about 20 countries and is planned to be available in more countries in the future.

With positive clinical data on recovery up to several months after a stroke, with the support and involvement of international key opinion leaders, and with ongoing post-marketing experience, NeuroAiD™ is the only available agent for post-stroke rehabilitation.

Prescription Information

Recommended treatment includes four capsules at a time, three times a day. Standard treatment will last four to twelve weeks.

Route of administration: oral administration

NeuroAiD™ capsules can be:

• swallowed as such with water
• opened and drunk once powder has been diluted in water
• opened and administered via a gastric tube once powder has been diluted in water

Interaction

To date, no harmful interactions between NeuroAiD™ and any other medicinal compound or between NeuroAiD™ and prescribed/OTC drugs have been observed. As a routine precaution, patients on an oral anticoagulant are advised to have their INR monitored initially in a similar way as for any changes in their prescription.

Side effects

Post-marketing pharmacovigilance has received two reported incidences of dry mouth. Contraindications: the use of NeuroAiD™ in pregnancy and lactating women is not well established. No contraindications are known to date.

Email Print PDF